Dual blockage with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy.

Trial Profile

Dual blockage with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Afatinib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms DAFNE
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 16 Jul 2013 Planned End Date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top